Missed Approval But Q2 Looks Promsing

NASDAQ:UTHR   United Therapeutics Corporation
More things down the pipeline to come, and this company is making tons of money. This price is going to fill the gap for sure and stay above 200 in Q2.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.